Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study results
Aim. To compare the effectiveness of the combination therapy with ivabradine and β-adrenoblockers (β-AB) and the dose-titration β-AB therapy. Material and methods. This multi-centre, open, controlled study included 1104 patients with functional Class (FC) II-III stable angina (SA), sinus rhythm, and...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
1970-01-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/2069 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849250418462294016 |
|---|---|
| author | Yu. A. Karpov M. G. Glezer Yu. A. Vasyuk R. T. Saygitov E. L. Shkolnik |
| author_facet | Yu. A. Karpov M. G. Glezer Yu. A. Vasyuk R. T. Saygitov E. L. Shkolnik |
| author_sort | Yu. A. Karpov |
| collection | DOAJ |
| description | Aim. To compare the effectiveness of the combination therapy with ivabradine and β-adrenoblockers (β-AB) and the dose-titration β-AB therapy. Material and methods. This multi-centre, open, controlled study included 1104 patients with functional Class (FC) II-III stable angina (SA), sinus rhythm, and heart rate (HR) ≥60 bpm, who received regular β-AB therapy in submaximal doses. The participants were divided into the standard therapy group (β-AB therapy with the dose titration to the maximal tolerated dose; 228 patients (20,7%)) and the ivabradine therapy group (876 patients (79,3%))Results. Both groups were comparable by main demographical and clinical characteristics. Adding ivabradine to the β-AB therapy resulted in a more pronounced HR reduction at Week 16, compared to the standard therapy group (61±6 vs. 63±8 bpm; p=0,001). By the end of the study, the percentage of the patients with FC I SA was significantly higher in the ivabradine group than in the standard therapy group (37,1% vs. 28%; p=0,017). The average number of angina attacks between Weeks 8 and 16 was significantly lower in the ivabradine group than in the standard therapy group – 4 (2;10) vs. 6 (2;15), respectively (p=0,015). In the standard therapy group, the incidence of adverse events, such as dyspnoea, hypotension, and fatigue, was significantly higher than in the ivabradine group – 18,4% vs. 9,4%, respectively (p<0,001). Conclusion. In SA patients, the combination therapy with β-AB and ivabradine demonstrated good tolerability, safety, and high antianginal effectiveness, which resulted in a more pronounced clinical improvement, compared to the dose-titration β-AB therapy. |
| format | Article |
| id | doaj-art-e2abe53887a246858b49c3c7768ec75d |
| institution | Kabale University |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| publishDate | 1970-01-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj-art-e2abe53887a246858b49c3c7768ec75d2025-08-20T03:57:17Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01251970-01-0110883891781Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study resultsYu. A. Karpov0M. G. Glezer1Yu. A. Vasyuk2R. T. Saygitov3E. L. Shkolnik4Russian Cardiology Scientific and Clinical ComplexI.M. Sechenov First Moscow State Medical UniversityMoscow State Medico-Stomatological UniversityI.M. Sechenov First Moscow State Medical UniversityMoscow State Medico-Stomatological UniversityAim. To compare the effectiveness of the combination therapy with ivabradine and β-adrenoblockers (β-AB) and the dose-titration β-AB therapy. Material and methods. This multi-centre, open, controlled study included 1104 patients with functional Class (FC) II-III stable angina (SA), sinus rhythm, and heart rate (HR) ≥60 bpm, who received regular β-AB therapy in submaximal doses. The participants were divided into the standard therapy group (β-AB therapy with the dose titration to the maximal tolerated dose; 228 patients (20,7%)) and the ivabradine therapy group (876 patients (79,3%))Results. Both groups were comparable by main demographical and clinical characteristics. Adding ivabradine to the β-AB therapy resulted in a more pronounced HR reduction at Week 16, compared to the standard therapy group (61±6 vs. 63±8 bpm; p=0,001). By the end of the study, the percentage of the patients with FC I SA was significantly higher in the ivabradine group than in the standard therapy group (37,1% vs. 28%; p=0,017). The average number of angina attacks between Weeks 8 and 16 was significantly lower in the ivabradine group than in the standard therapy group – 4 (2;10) vs. 6 (2;15), respectively (p=0,015). In the standard therapy group, the incidence of adverse events, such as dyspnoea, hypotension, and fatigue, was significantly higher than in the ivabradine group – 18,4% vs. 9,4%, respectively (p<0,001). Conclusion. In SA patients, the combination therapy with β-AB and ivabradine demonstrated good tolerability, safety, and high antianginal effectiveness, which resulted in a more pronounced clinical improvement, compared to the dose-titration β-AB therapy.https://cardiovascular.elpub.ru/jour/article/view/2069stable anginatreatmentβ-adrenoblockersquality of lifeivabradine |
| spellingShingle | Yu. A. Karpov M. G. Glezer Yu. A. Vasyuk R. T. Saygitov E. L. Shkolnik Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study results Кардиоваскулярная терапия и профилактика stable angina treatment β-adrenoblockers quality of life ivabradine |
| title | Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study results |
| title_full | Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study results |
| title_fullStr | Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study results |
| title_full_unstemmed | Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study results |
| title_short | Antianginal effectiveness and tolerability of ivabradine in patients with stable angina: CONTROL-2 Study results |
| title_sort | antianginal effectiveness and tolerability of ivabradine in patients with stable angina control 2 study results |
| topic | stable angina treatment β-adrenoblockers quality of life ivabradine |
| url | https://cardiovascular.elpub.ru/jour/article/view/2069 |
| work_keys_str_mv | AT yuakarpov antianginaleffectivenessandtolerabilityofivabradineinpatientswithstableanginacontrol2studyresults AT mgglezer antianginaleffectivenessandtolerabilityofivabradineinpatientswithstableanginacontrol2studyresults AT yuavasyuk antianginaleffectivenessandtolerabilityofivabradineinpatientswithstableanginacontrol2studyresults AT rtsaygitov antianginaleffectivenessandtolerabilityofivabradineinpatientswithstableanginacontrol2studyresults AT elshkolnik antianginaleffectivenessandtolerabilityofivabradineinpatientswithstableanginacontrol2studyresults |